Press coverage about Applied Genetic Technologies (NASDAQ:AGTC) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7437106180005 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

AGTC has been the subject of several research reports. Zacks Investment Research cut shares of Applied Genetic Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. ValuEngine raised shares of Applied Genetic Technologies from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 20th. Finally, HC Wainwright set a $8.00 price objective on shares of Applied Genetic Technologies and gave the company a “buy” rating in a research note on Monday, August 20th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $8.21.

Shares of Applied Genetic Technologies stock traded up $0.07 during mid-day trading on Friday, hitting $4.45. The stock had a trading volume of 400 shares, compared to its average volume of 71,639. Applied Genetic Technologies has a 12-month low of $3.25 and a 12-month high of $5.75. The stock has a market cap of $81.04 million, a price-to-earnings ratio of 222.50 and a beta of 2.14.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Featured Story: Leveraged Buyout (LBO) Explained

Insider Buying and Selling by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with's FREE daily email newsletter.